Raymond James & Associates Astrazeneca PLC Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Astrazeneca PLC stock. As of the latest transaction made, Raymond James & Associates holds 2,429,269 shares of AZN stock, worth $162 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,429,269
Previous 2,576,736
5.72%
Holding current value
$162 Million
Previous $201 Million
5.81%
% of portfolio
0.12%
Previous 0.13%
Shares
30 transactions
Others Institutions Holding AZN
# of Institutions
1,349Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.19 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.8 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.48 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.45 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.27 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $206B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...